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Background: Neural-cadherin (N-cadherin) is one of the most important molecules involved in tissue
morphogenesis, wound healing, and the maintenance of tissue integrity. Recently, the cleavage of N-cadherin has
become a focus of attention in the field of cancer biology. Cadherin and their ectodomain proteolytic shedding
play important roles during cancer progression. The aims of this study are to investigate the serum soluble
N-cadherin (sN-CAD) levels in patients with malignant bone and soft tissue tumors, and to evaluate the prognostic
significance of the sN-CAD levels.
Methods: We examined the level of serum sN-CAD using an ELISA in 80 malignant bone and soft tissue tumors
(bone sarcoma, n = 23; soft tissue sarcoma, n = 50; metastatic cancer, n = 7) and 87 normal controls. The mean
age of the patients was 51 years (range, 10–85 years) and the mean follow-up period was 43 months (range,
1–115 months).
Results: The median serum sN-CAD level was 1,267 ng/ml (range, 135–2,860 ng/ml) in all patients. The mean
serum sN-CAD level was 1,269 ng/ml (range, 360–2,860 ng/ml) in sarcoma patients, otherwise 1,246 ng/ml (range,
135–2,140 ng/ml) in cancer patients. The sN-CAD levels in patient were higher than those found in the controls,
who had a median serum level of 108 ng/ml (range, 0–540 ng/ml). The patients with tumors larger than 5 cm had
higher serum sN-CAD levels than the patients with tumors smaller than 5 cm. The histological grade in the patients
with higher serum sN-CAD levels was higher than that in the patients with lower serum sN-CAD levels. A univariate
analysis demonstrated that the patients with higher serum sN-CAD levels showed a worse disease-free survival rate,
local recurrence-free survival rate, metastasis-free survival rate, and overall survival rate compared to those with
lower serum sN-CAD levels. In the multivariate analysis, sN-CAD was an independent factor predicting disease-free
survival.
Conclusions: sN-CAD is a biomarker for malignant bone and soft tissue tumors, and a potentially valuable
pre-therapeutic prognostic factor in patients with bone and soft tissue sarcoma.
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Musculoskeletal sarcoma is a rare malignancy. Despite
the recent advances in treatment for these tumors, the
prognosis is still poor. To improve the clinical outcomes
of sarcoma patients, the discovery of the mechanisms of
tumorigenesis and the identification of early biomarkers
for determining the diagnosis/prognosis are required. In* Correspondence: matsumin@clin.medic.mie-u.ac.jp
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reproduction in any medium, provided the orparticular, the identification of a biomarker that can
predict patients at high-risk is important, because such
a biomarker could be a useful indicator for determi-
ning whether adjuvant therapeutic modalities, such as
irradiation and chemotherapy, should be utilized.
The etiology of tumors is multifactorial, and is believed
to be the result of inappropriate cell growth, faulty cell dif-
ferentiation and improper cell–cell and cell–extracellular
matrix interactions. In particular, cell-cell adhesion is im-
portant in maintaining the tissue architecture. Cadherins
are one of the most important proteins involved in cell-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient and tumor characteristics




























1 two patients with multiple sarcomas were excluded.
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family of transmembrane glycoproteins that mediate
calcium-dependent intercellular adhesion. More than 40
members of the cadherin family have been identified so
far [1]. Cytoplasmic domain of the cadherin molecule can
form a molecular complex with the catenin family, which
link the cadherin to the actin cytoskeleton of the cell. The
cadherin-dependent signaling affects fundamental cellular
processes such as proliferation, survival, differentiation,
cell shape and migration, which in turn influence the
tissue morphogenesis and structure. The signaling is also
involved in pathogenic events such as carcinogenesis and
distant metastasis [2,3]. The loss of cell growth control
and architecture disruption is hallmarks of oncogenic
transformation. Previous studies have provided evidence
that the loss of adhesiveness and increased invasive
capacity of tumors cells are associated with a disruption of
cell-cell adhesion mediated by malfunction or altered
phosphorylation of the cadherin-catenin complex [4-7].
Recent studies showed that N-cadherin can be cleaved
by ADAM10 (a disintegrin and metalloproteinase 10). The
metalloproteinase domain of the enzyme is responsible for
the initial step of N-cadherin processing, which releases
soluble active fragments into the extracellular space, and
subsequently generates an intracellular C-terminal frag-
ment (CTF) [8,9]. The CTF initiates signaling pathways
through the cytoplasmic β-catenin pool. Therefore, the
ADAM10-dependent cleavage of N-cadherin modulates
cell-cell adhesion, as well as signal transduction.
Recently, many researchers have reported that cadherins
and their ectodomain shedding play important roles
during cancer progression. A multitude of extracellular
proteinases have been identified, and proteolytic shedding
of the extracellular domain results in the generation of sol-
uble E-, P- or N-cadherin ectodomains. Elevated levels of
circulating soluble E- and P-cadherins have been described
in cancer patients compared with healthy controls. For
example, Chan et al. showed that the soluble E-cadherin
concentration was significantly elevated in 67% of patients
with gastric cancer [10]. Soluble N-cadherin (sN-CAD)
can be found in the circulation of normal individuals, but
is elevated in patients with breast, prostate and bladder
carcinoma [11-14]. However, to date, there have been
no studies that have investigated the use of the serum
sN-CAD levels as a diagnostic or predicting factor.
The aims of this study are to investigate the serum
sN-CAD levels in patients with malignant bone and soft
tissue tumors, and to evaluate the prognostic significance
of the sN-CAD levels.
Methods
Patient selection
Serum samples were collected from 87 healthy subjects,
73 bone and soft tissue sarcoma patients, and 7metastatic cancer patients with musculoskeletal metasta-
ses. The details of the clinicopathological features of 73
patients of the bone and soft tissue sarcoma are listed in
Table 1. The mean follow-up period was 43 months
(range, 1–115 months). The patient group included 36
males and 37 females, with a mean age of 51 years
(range, 10–85 years) at the first presentation. There
were 23 bone sarcomas, including 14 osteosarcomas
(OS), 3 chondrosarcomas, 3 Ewing sarcomas, and 3
chordomas. There were also 50 soft tissue sarcomas,
including 10 malignant fibrous histiocytomas (MFH), 9
liposarcomas (5 myxoid liposarcomas, 2 pleomorphic
liposarcomas, and 2 dedifferentiated liposarcomas), 6
malignant peripheral nerve sheath tumors (MPNST), 3
synovial sarcomas, 3 dermatofibrosarcoma protuberans,
3 rhabdomyosarcomas, 2 epithelioid sarcomas, 2 clear
cell sarcomas, an extraskeletal chondrosarcoma, an
Niimi et al. BMC Cancer 2013, 13:309 Page 3 of 10
http://www.biomedcentral.com/1471-2407/13/309extraskeletal osteosarcoma, a myxofibrosarcoma, a ma-
lignant granular cell tumor, and 8 unclassifiable spindle
cell sarcomas. There were six metastatic cancer to the
bone (2 thyroid cancers, 2 renal cancers, 1 lung cancer,
and 1 multiple myeloma), and one metastatic cancer to
the soft tissue (squamous cell carcinoma). A histological
grading of the bone sarcoma was performed according
to the grading system proposed by Borders AC [15] and
a histological evaluation of soft tissue sarcoma was
performed using the grading system of the French
Federation of Cancer Centers Sarcoma Group system
[16]. The histological grading in soft tissue sarcoma was
low grade (grade 1) in 9 sarcomas and in high grade 41
sarcomas (grade 2:20, grade 3:21), while the histological
grading in bone sarcoma was low grade in 4 sarcomas
and high grade in 19 sarcomas. All patients underwent
a complete tumor resection with a wide margin during
the initial surgery at our hospital. The diagnoses were
primarily based on the morphological appearance based
on the results of their reactivity for immunostaining.
The 73 samples consisted of 50 primary lesions, 17 local
recurrences, and 6 metastases.
At the final follow-up, 26 patients were continuously
disease-free, 13 patients had no evidence of disease, 15
patients were alive with disease, and 19 patients died of
disease.
The control subjects comprised 28 males and 59
females. The mean age of the control subjects was
46 years (range, 19–89 years). Almost all control sub-
jects younger than 60 years old were healthy volunteers
without any medical history of cancer. Those over
60 years of age had conditions such as osteoarthritis,
osteoporosis, and so on, and all had C-reactive protein
values below 0.5 mg/dl.
This study is in compliance with the principles of the
Declaration of Helsinki and written informed consent
was obtained from all of the patients included in this
study.Serum sample collection and storage
Fifty-one serum samples were obtained at open biopsy
or initial surgical excision before administration of any
chemotherapeutic agent. Seventeen serum samples were
obtained at the excision of recurrent tumor. Five serum
samples were obtained at the excision of the metastatic
lesion. Longitudinal change of the sN-CAD was mea-
sured by measuring the serum level at the pre- and post-
operative day in a metastatic epitheliod sarcoma patient.
Venous blood samples were collected and centrifuged at
2,500 g for 10 min. All sera were stored at −80°C until
measurement. All samples were collected under the
approval of the ethics committee of the Mie University
Graduate School of Medicine.Immunoenzymometric assay for the sN-CAD levels
The immunoenzymometric assay for the sN-CAD levels
was performed using a home-made ELISA plate, as
described in a previous report [17]. All serum samples
were diluted 5 times in PBS containing 0.1% bovine
serum albumin (BSA). A dilution series of recombinant
N-cadherin from 1 to 1,000 ng/ml was prepared (recom-
binant human N-cadherin/Fc chimera, R&D Systems,
Abingdon, UK). A 96 well immunoplate (CN-469949,
Nalge Nunc International, Denmark) was coated with 75 μl
of the diluted sample overnight at 4°C. The wells were
washed with PBS/0.05% Tween-20 and quenched at 37°C
with PBS/1% BSA for 1 hr. Next, the plates were washed
again (4 times) and incubated with the primary antibody
(Mouse GC-4 antibody, Sigma, St. Louis, MO; 1/200 in
PBS/0.1% BSA) at 37°C for 2 hr. The plates were then
washed again (4 times), and subsequently incubated
with a mouse secondary antibody linked to alkaline
phosphatase (Goat anti-mouse linked to alkaline phos-
phatase, Sigma, St. Louis, MO; 1/3,000). The substrate,
p-nitrophenylphosphate (N2765, Sigma, St. Louis, MO),
was added to the plates, and after 30 min, the optical
density of each well was determined with a microplate
reader (Molecular Devices, Wokingham, UK) at 405 nm.
Measurements were done at least in a triplet for each sam-
ple, and the mean value was calculated.
Statistical analysis
The Mann–Whitney U test was used to analyze the
association of the serum sN-CAD levels between healthy
subjects and patients. The Mann–Whitney U test was
also used to analyze the associations between the serum
sN-CAD levels and the clinicopathological variables,
such as the type of tumor (bone or soft tissue sarcoma),
age, tumor depth, tumor size, histological grade, and the
type of malignancy (primary or recurrence/metastasis).
We defined the cut-off level of sN-CAD at 1,500 ng/ml
to identify the high-risk patient group. The disease-free
survival (DFS) was defined as the time from the initial
treatment to the date of clinically documented local re-
currence/metastasis. The local recurrence-free survival
(LRFS) was defined as the time from the initial treat-
ment to the date of clinically documented local recur-
rence. The metastasis-free survival (MFS) was defined as
the time from the initial treatment to the date of clinic-
ally documented distant metastasis. The overall survival
(OS) was defined as the time from the initial treatment
to the date of death from any cause. For the multivariate
analysis, a Cox proportional hazards regression model
was used to identify the statistically significant diffe-
rences in the survival and to estimate hazard ratios and
95% confidence intervals. The prognostic variables by
the univariate analysis with a p < 0.2 (age, tumor size,
histological grading, and sN-CAD) were entered into a
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sidered to be significant. The analysis was performed using
the StatView statistical software package (version 5.0; SAS
Institute, Cary, NC, USA). The statistical analysis was
performed by N.R. and M.A., and both of whom have
responsibility for the results of statistical analysis.
Results
Serum sN-CAD levels in sarcoma patients, cancer patients,
and control subjects
The mean serum sN-CAD level was 1,267 ng/ml (range,
135–2,860 ng/ml) in all patients. The mean serum
sN-CAD level was 1,269 ng/ml (range, 360–2,860 ng/ml)
in sarcoma patients, otherwise 1,246 ng/ml (range, 135–
2,140 ng/ml) in cancer patients with musculoskeletal me-
tastases. The levels measured in the patients were higher
than those found in the controls, who had a mean serum
level of 108 ng/ml (range, 0–540 ng/ml; p < 0.01, Figure 1).
sN-CAD levels in the major sarcoma subgroups and con-
trol subjects were indicated in Figure 2. In the controls,
levels of sN-CAD under 500 ng/ml were observed,
whereas in the sarcoma patients, a wide distribution of
sN-CAD levels was observed. Longitudinal change of the
sN-CAD was measured in a metastatic epitheliod sarcoma
patient. The serum sN-CAD level showed 700 ng/ml just
before tumor excision and 525 ng/ml on the next day after
surgery.
Associations between the serum sN-CAD level and the
clinicopathological variables
The Mann–Whitney U test was used to analyze the
associations between the serum sN-CAD levels and theFigure 1 Serum sN-CAD levels in control subjects and in all patients.
sera of 87 control subjects and 73 sarcoma patients. The significance of dif
The levels of sN-CAD in the control subjects were less than 500 ng/ml, wh
a wide range.clinicopathological variables (Table 2). The patients with
tumors larger than 5 cm had higher serum sN-CAD
levels than the patients with tumors smaller than 5 cm.
The histological grade in the patients with higher serum
sN-CAD levels was higher than that in the patients with
lower serum sN-CAD levels. The levels of serum sN-CAD
were not also associated with the type of tumor (bone
or soft tissue sarcoma), tumor location, or the condition
(primary or recurrence/metastasis) of the lesion.
Prognostic analysis
The disease-free survival rate and predictors of events
We next compared the OS, DFS, LRFS, and MFS be-
tween the patients with high serum sN-CAD levels and
the patients with low serum sN-CAD levels. Patients
with high sN-CAD levels had a poorer DFS than the pa-
tients with low sN-CAD levels (p = 0.0022, Table 3). The
estimated DFS at 1, 3 and 5 years was 30.0%, 15.0%, and
0%, respectively, versus 65.7%, 55.1%, and 55.1%, re-
spectively, for patients with high and low sN-CAD levels
(Figure 3). A univariate analysis also revealed that there
was a significantly poorer outcome for patients with a
high tumor histological grade (p = 0.0334, Table 3). The
multivariate analysis demonstrated that the sN-CAD
levels is an independent prognostic factor (p = 0.0132;
Table 4).
Local recurrence-free survival rate and predictors of
events
The patients with high sN-CAD levels had a poorer LRFS
than the patients with low sN-CAD levels (p = 0.0123,
Table 3). The estimated LRFS at 1, 3 and 5 years wasBox plots representing the levels of soluble N-cadherin (sN-CAD) in the
ferences was determined using the Mann–Whitney U test (p <0.001).
ile the levels of sN-CAD in the sarcoma patients were distributed over
Figure 2 Distrubution of sN-CAD Levels in sarcoma patient s and in control subjects. Boxplot showed sN-CAD levels separately for the
major bone sarcomas, soft tissue sarcomas and control subjects.
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87.9% and 83.5% respectively, for patients with high and
low sN-CAD levels (Figure 4). The high sN-CAD levels
lost their prognostic significance in the multivariate
analysis (p = 0.1743).
The metastasis-free survival rate and predictors of events
The patients with high sN-CAD levels had a poorer MFS
than the patients with low sN-CAD levels (p = 0.0107,Table 2 The results of the univariate analysis of the
associations between the serum soluble N-cadherin levels








Bone tumor 23 1,281 (560–2,575) 0.8914
Soft tissue tumor 50 1,264 (360–2,860)
Age (years) 0.4665
≦49 32 1,232 (525–2,860)
≧50 41 1,298 (360–2,580)
Tumor size 1 0.0362
<5 cm 17 1,025 (360–1,900)
≧5 cm 56 1,343 (360–2,860)
Depth 2 0.5402
Superficial 6 1,364 (390–2,180)
Deep 67 1,261 (360–2,860)
Histological grading 0.0482
Low grade 14 1,050 (540–2,575)
High grade 59 1,321 (360–2,860)




1 two patients with multiple sarcomas were excluded.Table 3). The estimated MFS at 1, 3 and 5 years was
43.7%, 43.7%, and 34.9%, respectively, versus 63.1%, 55.4%
and 51.0%, respectively, for the high and low sN-CAD
levels (Figure 5). A univariate analysis also revealed that
there was a significantly poorer outcome for patients with
large tumors (p = 0.0159) and high tumor histological
grades (p = 0.0108) (Table 3).
The overall survival rate and predictors of events
Patients with high sN-CAD levels had a poorer OS than
the patients with low sN-CAD levels (p = 0.0334,
Table 3). The estimated OS at 1, 3 and 5 years was
84.0%, 50.4%, and 50.4%, respectively, versus 93.7%,
78.4% and 73.0%, respectively, for patients with high and
low sN-CAD levels (Figure 6). A univariate analysis also
revealed that there was a significantly poorer outcome for
patients with high tumor histological grades (p = 0.004,
Table 3). However, both the high sN-CAD levels lost
their prognostic significance in the multivariate analysis
(Table 5).
Discussion
In the present study, we found that the serum levels of
sN-CAD in patients with malignant bone and soft tissue
tumors were higher than those in control subjects. Both
the tumor size and the histological grade were positively
correlated to the serum sN-CAD levels. The current uni-
variate analyses showed that high serum sN-CAD levels
were associated with a decreased OS, DFS, MFS, and
LRFS. Multivariate analyses showed an association of a
high serum sN-CAD level with a decreased DFS. These
results suggest that sN-CAD is a biomarker, and may
potentially be valuable as a pre-therapeutic prognosic
factor in patients with malignant bone and soft tissue
tumors. To the best of our knowledge, this is the first






















≦49 23 60.9% 0.1603 25 90.0% 0.0621 32 58.9% 0.5899 32 81.8% 0.0517
≧50 32 30.5% 31 62.4% 40 46.1% 41 56.0%
Gender
Male 26 50.2% 0.5806 29 76.1% 0.6890 36 60.4% 0.4844 36 68.8% 0.7350
Female 29 35.4% 27 76.5% 36 44.8% 37 66.1%
Size (cm)
<5 14 66.1% 0.0616 13 82.5% 0.9879 17 43.5% 0.0159 17 83.3% 0.1327
≧5 41 34.5% 43 73.4% 55 79.5% 56 63.0%
Depth
Superficial 3 66.7% 0.8647 3 66.7% 0.6414 6 62.5% 0.6888 6 75.0% 0.7062
Deep 52 42.1% 53 76.9% 66 51.0% 67 66.7%
Location 1
Trunk 16 34.4% 0.2593 13 65.6% 0.3231 24 54.7% 0.8741 25 69.4% 0.7125
Extremity 37 48.9% 43 77.9% 46 52.7% 46 67.1%
Histological grading
Low grade 13 69.2% 0.1171 13 100% 0.1026 14 84.6% 0.0108 14 91.7% 0.0426
High grade 42 31.4% 43 67.2% 58 58.4% 59 60.5%
Soluble Cadherin 2
Low 40 55.1% 0.0022 40 83.5% 0.0123 51 51.0% 0.0107 52 73.0% 0.0334
High 15 0% 16 60.6% 21 34.9% 21 50.4%
1 two patients with multiple sarcoms were excluded.
2 Low means <1,500 ng/ml, and high means ≧1,500 ng/ml.
3 Log-rank test.
Figure 3 The cumulative disease-free survival (DFS) of patients with high sN-CAD levels, compared to patients with low sN-CAD levels.
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Age (years) 2.796 0.608-12.856 0.1865
≦49
≧50
Size (cm) 1.474 0.279-7.796 0.6483
<5
≧5
Histological grading 0.075 0.005-1.045 0.0540
Low grade
High grade
Soluble Cadherin 1 6.540 1.480-28.902 0.0132
Low
High
1 Low means < 1,500 ng/ml, and high means ≧ 1,500 ng/ml.
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http://www.biomedcentral.com/1471-2407/13/309report which indicated the significance of sN-CAD as a
biomarker for prognosis in malignant bone and soft tis-
sue tumor patients.
Recently, accumulating evidence has suggested epithelial-
mesenchymal transition (EMT) to play a critical role in
cancer progression [18]. The EMT is defined by the loss
of epithelial characteristics and the acquisition of a
mesenchymal phenotype. The cell characteristics are
highly affected during the EMT, resulting in altered
cell-cell and cell-matrix interactions, and increased cell
motility and invasiveness. In epithelial cancers, the EMT is
characterized by a switch in cell membrane cadherins
(from E- to N-cadherin), a change from apical–basal toFigure 4 The cumulative local recurrence-free survival (LRFS) of patie
sN-CAD levels.front–back polarity and the acquisition of motility, en-
abled in part by the restructuring of the actin cytoskeleton
[19]. The EMT is associated with the invasion and me-
tastasis of various cancers [14,20-23]. Because sarcoma
cells have a mesenchymal phenotype, N-cadherin may
be one of the key molecules involved in disease progres-
sion. However, only a small number of studies about N-
cadherin expression in bone and soft tissue sarcoma
have been reported. Laskin et al. [24] described that N-
cadherin was observed in chordoma (100%), biphasic
synovial sarcoma (86%), diffuse mesothelioma (70%),
malignant melanoma (56%), epithelioid sarcoma (38%),
epithelioid angiosarcoma (25%), poorly differentiated
synovial sarcoma (15%), clear cell sarcoma (10%), and
monophasic fibrous synovial sarcoma (4%). Kashima
et al. [25] found a reduced expression of N-cadherin on
the osteosarcoma cell surface, and suggested that the
reduced expression of N-cadherin might be due to the
proteolytic cleavage of the intact form into the secreted
form. However, no study has so far assessed the relation-
ship between the sN-CAD levels and their clinical signifi-
cance in patients with bone and soft tissue tumors.
The present study showed that the serum sN-CAD
levels were correlated with the tumor size (p = 0.02).
The several possible causes of the increased levels of sN-
CAD in patients with larger tumors can be supposed.
First possibility is that the sN-CAD levels may depend
on the number of malignant cells. Larger tumor might
have a higher sN-CAD level because they are composed
of a higher number of cells. Second possibility is that the
expression and/or shedding of N-cadherin may increase
in rapidly growing tumors. In the current study, the uni-
variate analyses showed that high serum sN-CAD levelsnts with high sN-CAD levels, compared to patients with low
Figure 5 The cumulative metastasis-free survival (MFS) of patients with high sN-CAD levels, compared to patients with low sN-CAD
levels.
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LRFS. The multivariate analyses showed an association
of a high serum sN-CAD level with a decreased DFS.
Therefore, our results suggest that a higher sN-CAD
level is correlated with the local aggressiveness of the
tumor.
In the present study, we confirmed that, poor overall
survival was associated with high sN-CAD and high
histological grade in the univariate analysis. However,
sN-CAD was failed to demonstrate any association with
OS in multivariate analysis. The first possible reason is
that sN-CAD is not a strong predictor for OS comparedFigure 6 The cumulative overall survival (OS) of patients with high so
sN-CAD levels.with histological grading. The second possible reason is
that multivariate analysis couldn’t detect the sN-CAD as
a strong predictor for OS, because this study consists of
relatively small number of patients. Therefore, we think
that the larger scale study is necessary.
Recent studies have demonstrated that N-cadherin can
be cleaved by ADAM10, which is one of the ADAM
family members [8]. ADAM10 is a transmembrane pro-
tein involved in proteolysis and cell adhesion, and has
been implicated in the pathogenesis or progression of
several cancers, including uterine, ovarian, gastric and
colorectal cancer [26]. There have so far been no reportsluble N-cadherin (sN-CAD) levels, compared to patients with low









Age (years) 4.087 1.375-12.149 0.0113
≦49
≧50
Size (cm) 2.816 0.624-12.706 0.1779
<5
≧5
Histological grading 0.135 0.020-0.905 0.0391
Low grade
High grade
Soluble Cadherin 1 1.858 0.654-5.268 0.2450
Low
High
1 Low means <1,500 ng/ml, and high means ≧1,500 ng/ml.
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but Matsumura et al. demonstrated that ADAM10 was
expressed in a fibrosarcoma cell line [27]. The proteo-
lytic activity of ADAM10 is inhibited by TIMP-1 and 3
[6,8]. Down-regulation of TIMP-1,-3 lead to deregu-
lation of the TIMP-1, -3/ADAM10 pathway, with in-
creased N-cadherin shedding. In fact, Benassi et al. [28]
reported the TIMP-1 expression to be either weak or
negative in the majority of 53 high grade soft tissue sar-
coma samples, and concluded that low levels of negative
regulators of proteolysis may be related to the biological
aggressiveness of tumors. There was also a report dem-
onstrating a lack of TIMPs expression in almost all
high-grade osteosarcomas [29]. Other authors reported
that no or minimal expression of TIMP-1 was detected
in musculoskeletal sarcomas, and that there was a sig-
nificant decrease of serum the TIMP-1 levels in sarcoma
patients compared to healthy controls [30,31]. Therefore,
we believe that the high sN-CAD expression level in
high grade sarcoma patients might be the result of a dis-
ruption of the balance between the activation and sup-
pression of N-cadherin shedding. Further investigations
are therefore warranted.
The chief limitation of this study is the small number
of samples examined. As is always the case in studies
concerning bone and soft tissue sarcoma, a large number
of samples could not be collected due to the rarity of the
tumor. This makes it difficult to obtain blood samples
from a large number of patients with each histopath-
ology. In addition, bone and soft tissue sarcoma has a
variety of pathological classifications, and we were only
able to investigate a few samples from each pathological
classification. As a result, a statistical analysis could not
be performed for each pathological classification due tothe small number of samples. The second limitation is
that our samples were collected under various conditions,
such as from the patients with primary sarcoma, sarcoma
with multiple metastases, and so on. To improve the
efficacy of using sN-CAD as a biomarker, prospective lon-
gitudinal blood collection from numerous patients, for ex-
ample, collection of blood preoperatively, ximmediately
after surgery, and at the time when sarcoma recurs, is
indispensible to improve the reliability of sN-CAD as a
biomarker. The third limitation is concerning the cut-off
value. In this study, we determined the cut-off value in
consideration of mean sN-CAD and clinical impact. As
described above, a large number of samples could not
be collected due to the rarity of the tumor and adequate
cut-off value is not established. Further investigation is
warrant.
Despite these limitations, we believe that this study is
of great value for the diagnosis and treatment of these
tumors. Clinically, tumor factors such as tumor-node-
metastasis staging, differentiation, histological classifi-
cation, and the tumor size are known to have strong
prognostic value. However, a prognostic indicator that
could predict the operability, survival rate, and recurrence
rate before the pathology of a resected specimen is avail-
able (and, hence, before surgery) would be particularly
helpful. This would provide important guidance and clues
for the selection of an optimal therapeutic approach. In
this study, we identified that the pre-therapeutic level of
sN-CAD could serve such a purpose, and could be deter-
mined by using a simple enzyme-linked immunosorbent
assay.Conclusion
In conclusion, our results indicate that sN-CAD is
present in significantly higher amounts in patients with
malignant bone and soft tissue tumors than in healthy
subjects. In addition, a high serum sN-CAD level is
associated with a poor outcome in musculoskeletal
tumor patients. sN-CAD is therefore a potentially valu-
able pretherapeutic factor for predicting the long-term
survival in patients. Further studies involving a larger
sample and longer follow-up are necessary to verify
these results.
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